AbSorber's Test Identifies Patients With Increased Risk for Kidney Transplant Rejection
Posted on: Monday, 18 August 2008, 06:00 CDT
Regulatory News:
LinkMed's (STO:LMED) portfolio company AbSorber recently received FDA approval in the U.S. for its patented transplantation test XM-ONE(R). Now AbSorber has received further support for its transplantation test from a major clinical trial in which six well-reputed transplantation centers in the U.S. and Sweden participated. The results of the study show that XM-ONE(R) provides valuable information that refines the diagnostics of matching the right organ with the right patient, thereby increasing the probability of a successful transplantation.
Following recent FDA approval, XM-ONE(R) has received yet another positive breakthrough - this time the results of major clinical trials in which four U.S. and two Swedish well-reputed transplantation centers participated. The study was presented on August 14 at the global transplantation congress in Sydney by Professor Andrea Zachary, a renowned expert in the transplantation area, at John Hopkins University Hospital in Baltimore.
"The study demonstrates and confirms an increased frequency of rejection reactions among patients who test positive with XM-ONE(R), even in cases where conventional lymphocyte cross-match tests are unsuccessful in detecting donor-specific antibodies. Prior to now, we have not been able to be sure that we could detect these important non-HLA anti-bodies" says Professor Zachary.
"The study shows that we now, with XM-One, easily can get access to donor cells that allow detection of non-HLA anti-bodies. This in turn, improves donor-recipient pairing and kidney transplantation outcome", adds Professor Andrea Zachary.
From June 2005 to October 2006, a total of 195 patients were screened of which 147 patients met inclusion criteria and were therewith evaluated in the XM-ONE(R) clinical trials. Patients participating in the trials were from the Sahlgrenska University Hospital in Gothenburg, Johns Hopkins University School of Medicine in Baltimore, Ohio State University in Columbus, Massachusetts General Hospital in Boston, Baylor University Medical Center in Dallas and the Karolinska University Hospital in Huddinge.
"The study is a first step in building up a scientific knowledge base about and clinical acceptance of XM-ONE(R). The work has awakened great scientific interest and several other transplantation centers want to conduct their own independent trials with XM-ONE(R)," said associate professor Jan Holgersson, doctor and researcher at the Karolinska University Hospital and founder of AbSorber.
"XM-ONE(R) provides key, previously unattainable, information about donor/recipient compatibility that increases the probability of a successful transplantation. XM-ONE(R) opens up completely new possibilities for detecting antibodies that we previously were unable to identify," continued Mr. Holgersson.
"Using XM-ONE(R), we can now identify the extent of clinical problems related to anti-endothelium cell antibodies in patients undergoing transplantations," concludes Mr. Holgersson.
Also visit www.absorber.se and www.linkmed.se
AbSorber develops products that facilitate more successful transplantations. AbSorber's first product, the transplantation test XM-ONE(R), detects key antibodies responsible for post-transplantation rejection reactions. XM-ONE(R) is already CE marked and FDA approved for sales in the EU and U.S.
LinkMed, in collaboration with innovators, develops life science companies. By contributing entrepreneurship and capital, LinkMed has created a portfolio of twelve companies, six in biotechnology and six in medical technology. The company's principal owners are FastPartner, Koncentra Holding, and the founder Ingemar Lagerlof. The LinkMed share is listed on the OMX Nordic Exchange Stockholm in the small-cap sector (ticker:LMED).
This information was brought to you by Cision http://newsroom.cision.com
Source: Business Wire
Related Articles
- Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
- Algeta to Enroll US Patients Into Global Phase III ALSYMPCA Trial Following Successful End-of-Phase II Meeting With FDA
- AEterna Enters Second Stage of Patient Recruitment for Phase II Cancer Trial
- Cogentus Enrolls First European Patient in Phase III Study of Combination Drug
- Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
- Fralex Reaches 100th Patient Milestone in Fibromyalgia Study
- MEDecision's Patient Clinical Summary To Be Implemented By Memphis Managed Care Corporation
- Health Management Associates, Inc. Completes Acquisition of Cleveland Clinic Hospital, Naples, Florida
- 340B Prime Vendor Program Adds NitroMed, Inc. To Growing List of Companies Providing Low-Cost Drugs to Clinics, Hospitals and Programs for Low-Income Americans
- Presence of TT Virus Infection in Chronic Hepatitis Patients From a Hospital in New Delhi, India
 |
 |
User Comments (0)
RSS Feeds